GlassScriptPhysician profile
Li Liu
NPI 1295722627
$19,310.49
in general payments reported to CMS, 2019-2025
48 companies · $3,384 in 2025
The $3,384 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $1,622 · 2021: $2,536 · 2022: $3,221 · 2023: $3,350 · 2024: $3,823 · 2025: $3,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,556.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,932.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $2,841.66 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,397.27 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,236.62 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $933.52 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Almatica Pharma LLC | $817.19 | 2022-2025 | Loreev Xr, Gralise, Teriparatide |
| Glaxosmithkline, LLC. | $758.47 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $713.76 | 2020-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $606.66 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $591.07 | 2020-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $566.12 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $480.35 | 2021-2023 | |
| Ardelyx, INC. | $430.28 | 2024-2025 | Ibsrela |
| Amarin Pharma, INC. | $429.26 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $392.05 | 2020-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $384.57 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $350.93 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Oyster Point Pharma, INC. | $331.80 | 2023-2025 | Tyrvaya |
| Sunovion Pharmaceuticals INC. | $316.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $315.65 | 2019-2023 | Belsomra |
| Sumitomo Pharma America, INC. | $292.65 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $263.42 | 2024-2025 | Voquezna |
| Lundbeck LLC | $243.57 | 2023-2025 | Rexulti |
| Radius Health, INC. | $202.19 | 2023-2025 | Tymlos |
| Vivus LLC | $182.65 | 2022-2025 | Pancreaze |
| Astellas Pharma US INC | $181.59 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $112.58 | 2023-2025 | Rexulti |
| Gilead Sciences, INC. | $101.15 | 2021-2024 | Vemlidy |
| Pfizer INC. | $89.64 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $85.80 | 2022-2024 | Eliquis |
| Allergan, INC. | $70.34 | 2020 | |
| Esperion Therapeutics, INC. | $68.50 | 2022-2023 | Nexletol |
| Ibsa Pharma INC. | $65.12 | 2023 | Tirosint, Licart |
| Dexcom, INC. | $64.55 | 2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $64.21 | 2025 | Korlym |
| Lexicon Pharmaceuticals, INC. | $56.62 | 2024 | |
| Ironwood Pharmaceuticals, INC | $53.80 | 2024 | |
| Exact Sciences Corporation | $45.35 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Regeneron Healthcare Solutions, INC. | $32.42 | 2024 | Dupixent |
| Smith+Nephew, INC. | $31.90 | 2022 | |
| Alvogen INC | $24.19 | 2024 | Teriparatide |
| Arbor Pharmaceuticals, INC. | $23.96 | 2020 | |
| Emd Serono, INC. | $23.73 | 2024 | |
| Redhill Biopharma INC. | $23.28 | 2023 | Talicia |
| Biogen, INC. | $21.53 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.07 | 2021 | |
| Ascend Therapeutics US, LLC | $19.63 | 2022 | |
| Genentech USA, INC. | $18.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.